Cadrenal Therapeutics (NASDAQ:CVKD) CFO Matthew Szot Sells 1,700 Shares

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CFO Matthew Szot sold 1,700 shares of Cadrenal Therapeutics stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $13.99, for a total transaction of $23,783.00. Following the transaction, the chief financial officer directly owned 17,133 shares of the company’s stock, valued at approximately $239,690.67. This trade represents a 9.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Cadrenal Therapeutics Price Performance

CVKD stock opened at $14.06 on Thursday. The company has a fifty day moving average price of $12.50 and a two-hundred day moving average price of $14.04. Cadrenal Therapeutics, Inc. has a one year low of $8.74 and a one year high of $22.90. The stock has a market cap of $28.82 million, a price-to-earnings ratio of -1.58 and a beta of 0.96.

Cadrenal Therapeutics (NASDAQ:CVKD) last released its quarterly earnings data on Monday, August 11th. The company reported ($1.87) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.27). Research analysts anticipate that Cadrenal Therapeutics, Inc. will post -7.59 EPS for the current fiscal year.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.